Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that its President and CEO, Ted White, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. The presentation, scheduled for 2:15 – 2:55 PM ET, will allow attendees to hear about Verrica's advancements in dermatology therapeutics, especially their late-stage product candidate, VP-102, aimed at treating molluscum, common warts, and external genital warts. Additionally, Verrica is developing VP-103 for plantar warts and has entered a global licensing agreement with Lytix Biopharma AS for the commercialization of VP-315. A live webcast of the event will be available on Verrica's website and will remain accessible for 30 days after the conference.
- President and CEO Ted White to present at a significant healthcare conference.
- VP-102 aims to address major unmet needs in dermatology.
- Development of VP-103 for plantar warts shows pipeline expansion.
- Global licensing deal for VP-315 indicates strategic growth.
- Dependence on third parties may introduce risks and uncertainties.
- Potential delays or issues in the regulatory approval process could impact product launch.
WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023.
Event details:
Date: Monday, April 17, 2023
Time: 2:15 – 2:55 PM ET (Fireside Chat)
Location: Virtual
Participants may access a live webcast of the event through the following link:
https://wsw.com/webcast/needham129/vrca/2250664
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the approval of VP-102 for the treatment of molluscum, the timing of clinical trial completion for VP-315 and Verrica’s cash and cash equivalents being sufficient to support planned operations into the first quarter of 2024. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2022 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler
Chief Financial Officer
tkohler@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
What date is the 22nd Annual Needham Virtual Healthcare Conference?
What time will Ted White's presentation occur at the conference?
What is VP-102 and what conditions does it aim to treat?
What is the significance of the licensing agreement with Lytix Biopharma?
Where can I access the live webcast of the conference?
